Lumicell Revenue and Competitors
Estimated Revenue & Valuation
- Lumicell's estimated annual revenue is currently $8.5M per year.
- Lumicell received $28.7M in venture funding in December 2017.
- Lumicell's estimated revenue per employee is $152,393
- Lumicell's total funding is $33M.
Employee Data
- Lumicell has 56 Employees.
- Lumicell grew their employee count by 14% last year.
Lumicell Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $3.8M | 37 | 0% | N/A | N/A |
#2 | $3M | 23 | 0% | N/A | N/A |
#3 | $4M | 14 | 8% | N/A | N/A |
#4 | $4.5M | 14 | -12% | N/A | N/A |
#5 | $5630M | 6953 | 4% | $450M | N/A |
#6 | $4M | 14 | 8% | N/A | N/A |
#7 | $6.8M | 44 | 19% | $29.6M | N/A |
#8 | $12.6M | 49 | 26% | N/A | N/A |
#9 | $2M | 13 | 8% | $44M | N/A |
#10 | $54.6M | 207 | 16% | N/A | N/A |
What Is Lumicell?
Lumicell is a leader in the field of image-guided cancer surgery. Lumicell technology illuminates cancer cells in the tumor cavity, enabling physicians to take action in real time to improve patient outcomes. The company's lead product, consisting of a fluorescent optical contrast agent and a handheld illumination device, is currently under clinical investigation in patients undergoing breast cancer surgery. A planned pivotal study aims to evaluate the ability of the technology to reduce positive margin rates and reduce repeat surgeries while sparing healthy tissue. Lumicell technology is also being investigated in colorectal cancer, Barrett's Esophagus, pancreatic cancer, and brain metastases. In clinical studies to date, no cancer has been missed and the safety profile of the optical contrast agent has been demonstrated.
keywords:Biotechnology,Healthcare,Medical Devices,Medical Diagnostics,Pharmaceuticals
$33M
Total Funding
56
Number of Employees
$8.5M
Revenue (est)
14%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Lumicell News
Lumicell is a privately held company focused on innovative fluorescence-guided technologies for cancer surgery with the potential to improve...
Innoblative Designs last week named former Lumicell chief executive Kelly Londy as its new CEO. Apart from her two-year stint at the Lumicell ...
Lumicell said it completed enrollment in a Phase C feasibility clinical trial for its intraoperative breast cancer imaging system. The Newton, Mass ...
Lumicell- Experts are testing a new innovative imaging technology at Massachusetts General Hospital. The imaging technology can enhance ...
Other Companies in Wellesley
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $6.7M | 61 | 15% | N/A |
#2 | $6.2M | 63 | -3% | N/A |
#3 | $16.5M | 70 | -3% | N/A |
#4 | $18.1M | 72 | -5% | N/A |
#5 | $7.5M | 74 | 9% | N/A |
Lumicell Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2014-01-07 | $1.0M | B | Article | |
| 2016-05-09 | $6.8M | Undisclosed | Article | |
| 2017-07-13 | $Undisclosed | Undisclosed | Article | |
| 2017-10-25 | $20.7M | Undisclosed | Article | |
| 2017-12-08 | $28.7M | C | Launch Capital | Article |